23.86

1.69% -0.41

Maze Therapeutics Inc (MAZE)

Overview News Price History Discussions Forecast

Maze Therapeutics Inc stock is traded at $23.86, with a volume of 533.77K. It is down -1.69% in the last 24 hours and down -6.65% over the past month. Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.

Previous Close:

$24.27

Open:

$24.16

24h Volume:

533.77K

Relative Volume:

0.63

Market Cap:

$1.32B

Revenue:

$2.50M

Net Income/Loss:

$-131.12M

P/E Ratio:

-8.3922

EPS:

-2.8431

Net Cash Flow:

$-112.73M

1W Performance:

-0.29%

1M Performance:

-6.65%

6M Performance:

-40.87%

1Y Performance:

+79.26%

1-Day Range:

$23.50

$24.37

1-Week Range:

$22.71

$25.08

52-Week Range:

$9.83

$53.65

Maze Therapeutics Inc Stock (MAZE) Company Profile

Name

Maze Therapeutics Inc

Sector

Healthcare (1107)

Industry

Biotechnology (621)

Phone

(650) 850-5070

Address

171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO

Employee

141

Twitter

Next Earnings Date

2026-05-13

Latest SEC Filings

MAZE's Discussions on Twitter

Compare MAZE vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MAZE Maze Therapeutics Inc	23.86	1.34B	2.50M	-131.12M	-112.73M	-2.8431
VRTX Vertex Pharmaceuticals Inc	453.17	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	614.73	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	878.49	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	281.90	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	156.58	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-18-26	Initiated	Truist	Buy
Mar-10-26	Initiated	Mizuho	Outperform
Dec-04-25	Initiated	Wells Fargo	Overweight
Nov-14-25	Initiated	Raymond James	Outperform
Sep-02-25	Initiated	BTIG Research	Buy
Jul-23-25	Initiated	H.C. Wainwright	Buy
Jul-08-25	Initiated	Wedbush	Outperform

View All

Maze Therapeutics Inc Stock (MAZE) Latest News

Jun 13, 2026

Maze Therapeutics Phase 2 Kidney Data Sparks Questions On Upside And Risk - Yahoo Finance

Jun 13, 2026

Jun 12, 2026

MAZE Q1 2026 Earnings: Narrower Loss Surprises Analysts Amid Pipeline ProgressEarnings Acceleration Picks - The League of Women Voters of Texas

Jun 12, 2026

Jun 11, 2026

Maze Therapeutics (MAZE) director receives grant of 18,000 stock options exercisable at $23.58 - Stock Titan

Jun 10, 2026

Director Richard Scheller receives 18,000 Maze Therapeutics (MAZE) stock options - Stock Titan

Jun 10, 2026

Maze Therapeutics (MAZE) director Herve Hoppenot awarded 18,000 stock options at $23.58 - Stock Titan

Jun 10, 2026

18,000 Maze Therapeutics (MAZE) options granted to director Andrews - Stock Titan

Jun 10, 2026

Maze Therapeutics (MAZE) shareholders elect directors and ratify Ernst & Young - Stock Titan

Jun 10, 2026

MAZE: Lead assets show strong efficacy and safety, with pivotal trials and key data readouts set for 2026–2027 - TradingView

Jun 10, 2026

Jun 08, 2026

MAZE: Directors and auditor ratified by majority vote; no shareholder questions submitted - TradingView

Jun 08, 2026

MAZE: Both director nominees and the auditor appointment were approved by majority vote - TradingView

Jun 08, 2026

MAZE Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift StockBasic EPS Analysis - newsline.com

Jun 08, 2026

Jun 07, 2026

Maze Therapeutics (MAZE): 8 Oversold Stocks to Buy Right Now - Insider Monkey

Jun 07, 2026

Jun 06, 2026

Maze Therapeutics CEO Sells Shares Worth Around 847000 Dollars - HarianBasis.co

Jun 06, 2026

8 Oversold Stocks to Buy Right Now - insidermonkey.com

Jun 06, 2026

Jun 05, 2026

Maze Therapeutics' CEO Sold Over 30,000 Company Shares. What Does That Mean for Investors? - Yahoo Finance

Jun 05, 2026

Jun 03, 2026

Maze Therapeutics president sells $381k in common stock By Investing.com - Investing.com Australia

Jun 03, 2026

Maze Therapeutics president sells $381k in common stock - Investing.com

Jun 03, 2026

Maze Therapeutics (MAZE) CEO’s family trusts sell 6,643 shares - Stock Titan

Jun 03, 2026

Maze Therapeutics (MAZE) CMO sells 14,853 shares after option exercise - Stock Titan

Jun 03, 2026

Jun 02, 2026

Maze Therapeutics to Participate in Two Upcoming Investor Conferences - 富途牛牛

Jun 02, 2026

Maze Therapeutics (MAZE) CSBO exercises options, sells 7,500 shares under 10b5-1 plan - Stock Titan

Jun 02, 2026

Why Is Maze Therapeutics, Inc. (MAZE) Stock Down Today? - Meyka

Jun 02, 2026

Jun 01, 2026

Coloma trusts sell MAZE shares (MAZE) under Rule 144 notice - Stock Titan

Jun 01, 2026

May 29, 2026

Maze Therapeutics (MAZE) Edges Higher, Consolidating Between Support and ResistanceEarnings Miss Risk - The Legal Advocate

May 29, 2026